Effect of Renal Impairment on the Pharmacokinetics of NN9535
NCT00833716
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
62
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes
Diabetes Mellitus, Type 2
Renal Impairment
Interventions
DRUG:
semaglutide
Sponsor
Novo Nordisk A/S